Browse by Audience
Skip to content
Papers of the Week
Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States.
Authors
Starling AJ, Kymes S, Asher D, Soni-Brahmbhatt S, Karnik-Henry MAbstract
The efficacy and safety of eptinezumab for preventive migraine treatment in adults have been demonstrated in multiple, large-scale clinical trials. This non-interventional, retrospective, observational chart review was conducted to examine patient response to eptinezumab 100 mg or 300 mg every 12 weeks for 6 months in the clinical setting.